Sponsors (32)
The bill expands Medicare coverage for guideline‑based genetic testing, higher‑intensity screening, and preventive cancer surgery—improving detection and access for high‑risk beneficiaries—but does so at the cost of higher Medicare spending and added administrative complexity, with a risk of limiting some repeat testing and creating implementation disputes.
Medicare beneficiaries at elevated hereditary‑cancer risk gain coverage for guideline‑based germline mutation testing, improving identification of high-risk individuals and (by tying coverage to evidence‑based oncology guidelines) reducing inappropriate testing.
Medicare beneficiaries with pathogenic germline mutations gain coverage for more frequent, guideline‑recommended high‑risk cancer screening, increasing early detection for high‑risk patients and reducing out‑of‑pocket costs for those screenings.
Medicare beneficiaries who meet the statutory patient definition can have risk‑reducing cancer surgery covered as 'reasonable and necessary' when supported by evidence‑based guidelines, improving access to preventive surgical care.
Expanding coverage for genetic testing, higher‑frequency screening, and risk‑reducing surgery will increase Medicare spending and could put upward pressure on federal health expenditures, premiums, or other program resources.
Requiring guideline‑based coverage and new contractor determinations may increase administrative burden and complexity for providers and contractors, potentially delaying claims, care, or reimbursement during implementation.
The statute allows Medicare to deny payment for repeat germline testing for the same person, which could bar clinically indicated repeat tests in some cases and harm individual patient care.
Based on analysis of 4 sections of legislative text.
Requires Medicare to cover guideline-based germline genetic testing, to treat certain risk-reducing surgeries as medically necessary, and to expand screening frequency for mutation carriers.
Introduced July 23, 2025 by Debbie Wasserman Schultz · Last progress July 23, 2025
Expands Medicare coverage to pay for guideline-based germline (inherited) genetic testing for people with personal or family histories suggesting hereditary cancer, and disallows payment if the same test is done more than once for the same person. Declares risk-reducing surgery for eligible high-risk individuals to be medically necessary and covered, and requires Medicare to remove or relax screening frequency limits for beneficiaries found by genetic testing to carry a hereditary cancer gene mutation, aligning coverage with clinical guidelines and ensuring at least annual screening where appropriate.